# MIDAS (NCT04934475)

> MInimal Residual Disease Adapted Strategy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04934475
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Intergroupe Francophone du Myelome
- Conditions: Multiple Myeloma
- Interventions: Isatuximab; ASCT
- Enrollment: 791
- Primary outcome: Negative MRD rate
- Primary outcome: Negative MRD rate
- Primary outcome: Negative MRD rate
- Primary outcome: Negative MRD rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 75
- X threads: 71
- Podcasts: 33
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=midas-nct04934475

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04934475", "email": "<work email>"}; the inbox owner confirms by the emailed link.